Literature DB >> 2424862

The role of delay in stage III testicular tumours.

A Akdaş, Z Kirkali, D Remzi.   

Abstract

Twenty-nine patients with stage III testicular tumours seen between 1979 and 1984 were analysed for the relation between delay in both diagnosis and chemotherapy, and prognosis. The complete response (CR) rate was 40% for patients who were treated within 6 months from onset of symptoms, and 26.3% for patients who had an interval longer than 6 months. We believe that delay in diagnosis and chemotherapy may affect the response to treatment. Health education of the male population for self-examination of the testes is an important factor to minimize this delay.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2424862     DOI: 10.1007/bf02082606

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  6 in total

1.  Germ-cell testicular cancer in adults (first of two parts).

Authors:  E E Fraley; P H Lange; B J Kennedy
Journal:  N Engl J Med       Date:  1979-12-20       Impact factor: 91.245

2.  Chemotherapy of metastatic germ cell tumors.

Authors:  R B Golbey; T F Reynolds; D Vugrin
Journal:  Semin Oncol       Date:  1979-03       Impact factor: 4.929

3.  Impact of delay in diagnosis on clinical stage of testicular cancer.

Authors:  G J Bosl; N J Vogelzang; A Goldman; E E Fraley; P H Lange; S H Levitt; B J Kennedy
Journal:  Lancet       Date:  1981-10-31       Impact factor: 79.321

4.  Impact of symptomatic interval on prognosis of patients with stage III testicular cancer.

Authors:  H Scher; G Bosl; N Geller; C Cirrincione; W Whitmore; R Golbey
Journal:  Urology       Date:  1983-06       Impact factor: 2.649

5.  Vinblastine, bleomycin and cis-diamminedichloroplatinum in the treatment of advanced testicular carcinoma. Possible importance of longer induction and shorter maintenance schedules.

Authors:  G J Bosl; P H Lange; E E Fraley; L E Nochomovitz; J Rosai; N J Vogelzang; K Johnson; A Goldman; B J Kennedy
Journal:  Am J Med       Date:  1980-04       Impact factor: 4.965

6.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

  6 in total
  2 in total

1.  Cancer diagnostic tools to aid decision-making in primary care: mixed-methods systematic reviews and cost-effectiveness analysis.

Authors:  Antonieta Medina-Lara; Bogdan Grigore; Ruth Lewis; Jaime Peters; Sarah Price; Paolo Landa; Sophie Robinson; Richard Neal; William Hamilton; Anne E Spencer
Journal:  Health Technol Assess       Date:  2020-11       Impact factor: 4.014

Review 2.  Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review.

Authors:  R D Neal; P Tharmanathan; B France; N U Din; S Cotton; J Fallon-Ferguson; W Hamilton; A Hendry; M Hendry; R Lewis; U Macleod; E D Mitchell; M Pickett; T Rai; K Shaw; N Stuart; M L Tørring; C Wilkinson; B Williams; N Williams; J Emery
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.